<DOC>
	<DOCNO>NCT02878161</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) chronic disable disease . tumor necrosis factor-a ( TNF-a ) inhibitor demonstrate outstanding performance relieve joint inflammation retard bone erosion involve RA . However , still one-third RA patient poor response TNF α inhibitor . The Investigators hope discover prediction protein domestic genetic background finally establish prediction system Chinese characteristic .</brief_summary>
	<brief_title>Predictability Studies Efficacy TNF-α Inhibitors Chinese RA From `` Real World ''</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic disable disease . TNF-α inhibitor demonstrate outstanding performance relieve joint inflammation retard bone erosion involve RA . However , still one-third RA patient poor response TNF α inhibitor . Currently personalized biological treatment research hotspot . Recent study focus explore biomarkers predictive drug response . The research method genomics , transcriptomics , proteomics , metabolomics immunocytology , apply , successfully integrate . The related study China still initial stage , necessitate in-depth study area . The investigator ' preliminary study show TNF-α-308 gene polymorphism exist Chinese RA patient phosphoinositide 3-kinase/Akt signal pathway activate proliferated synovial fibroblast stimulate TNF-α . Therefore , first attempt China , investigator intend screen differential protein use isobaric tag relative absolute quantitation ( iTRAQ ) technique RA patient receive anti-TNF-α therapy , verify predictive effect select differential protein upstream gene polymorphism downstream protein expression . The investigator also explore mechanisms differential protein involve TNF-α related signal pathway use vitro gene transfer , siRNA interference , RA animal model . Through study investigator hope discover prediction protein domestic genetic background finally establish prediction system Chinese characteristic .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>sign consent voluntarily age 1875 year old patient meet American College Rheumatology ( ACR ) European League Against Rheumatism ( EULAR ) 2009 diagnostic criterion ( total score beyond 6 ) severe RA patient DAS28CRP≥5.1 The participant receive Infliximab plus Methotrexate invite enroll study . The participant receive Etanercept plus Methotrexate invite enroll study . The participant receive Adalimumab plus Methotrexate invite enroll study . The patient disease history disease cardiovascular , respiratory system , liver , gastrointestinal tract , endocrine , hematology , neurology psychiatric disturbance , investigator believe risk patient disease history disease use study drug , disease history disease disturb interpret data Patients cancer situ exist possibility cancer malignancy Basically completely loss mobility , lack selfcare ability , rely wheelchair bedridden . Experimental examination display follow : Aspartate aminotransferase alanine aminotransferase &gt; 1.5 time upper limit normal value Total bilirubin &gt; 1.5 time upper limit normal value Total white blood cell &lt; 2500 cells/L absolute neutrophil count &lt; 1200 cells/L lymphocyte count &lt; 750 cells/L platelet &lt; 100000/L Patients symptomatic herpes simplex Latent tuberculosis signal ( PPD+++ OR TSPOT &gt; 5 ) Positive result hepatitis B virus ( HBV ) : HBsAg + Or HBeAg + Or HBeAg + Or HBcAb + Or HBV DNA + hepatitis C virus ( HCV ) + HCV RNA + HIV infection HIV+ 1 month join group , clinical point view , patient serious infection cause virus , bacteria , fungi , parasite Pregnancy 、 location 、prepare conceive one year risk impregnate partner Patients receive biological therapy 6 month , participate clinical trial new drug A history drug allergy A history heavy drink vaccinate live vaccine recently</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>tumor necrosis factor α inhibitor</keyword>
	<keyword>predictive</keyword>
	<keyword>iTRAQ</keyword>
	<keyword>signal pathway</keyword>
</DOC>